- Home
- FLG vs CYTK Comparison
FLG vs CYTK Comparison
Compare FLG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLG
- CYTK
- Stock Information
- Founded
- FLG 1859
- CYTK 1997
- Country
- FLG United States
- CYTK United States
- Employees
- FLG N/A
- CYTK N/A
- Industry
- FLG
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- FLG
- CYTK Health Care
- Exchange
- FLG NYSE
- CYTK Nasdaq
- Market Cap
- FLG 4.9B
- CYTK 5.6B
- IPO Year
- FLG 1993
- CYTK 2004
- Fundamental
- Price
- FLG $11.24
- CYTK $34.34
- Analyst Decision
- FLG Buy
- CYTK Buy
- Analyst Count
- FLG 9
- CYTK 14
- Target Price
- FLG $13.33
- CYTK $70.92
- AVG Volume (30 Days)
- FLG 7.4M
- CYTK 1.4M
- Earning Date
- FLG 08-15-2025
- CYTK 08-07-2025
- Dividend Yield
- FLG 0.36%
- CYTK N/A
- EPS Growth
- FLG N/A
- CYTK N/A
- EPS
- FLG N/A
- CYTK N/A
- Revenue
- FLG $1,553,000,000.00
- CYTK $19,218,000.00
- Revenue This Year
- FLG $17.39
- CYTK $34.81
- Revenue Next Year
- FLG $27.21
- CYTK $643.79
- P/E Ratio
- FLG N/A
- CYTK N/A
- Revenue Growth
- FLG N/A
- CYTK 412.21
- 52 Week Low
- FLG $8.56
- CYTK $29.31
- 52 Week High
- FLG $13.35
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- FLG N/A
- CYTK 56.20
- Support Level
- FLG N/A
- CYTK $32.66
- Resistance Level
- FLG N/A
- CYTK $35.09
- Average True Range (ATR)
- FLG 0.00
- CYTK 1.27
- MACD
- FLG 0.00
- CYTK 0.22
- Stochastic Oscillator
- FLG 0.00
- CYTK 75.65
About FLG FLAGSTAR FINANCIAL INC
Flagstar Financial Inc operates over 400 branches, including a presence in the Northeast and Midwest and locations in high-growth markets in the Southeast and West Coast. In addition, the Bank has approximately 90 private banking teams located in over 10 cities in the metropolitan New York City region and on the West Coast, which serve the needs of high net-worth individuals and their businesses.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.